Loading...
Loading...
Browse all stories on DeepNewz
VisitPrimary ADC drug focus at AstraZeneca’s new facility
Drug A • 25%
Drug B • 25%
Drug C • 25%
Drug D • 25%
AstraZeneca product announcements, healthcare industry reports
AstraZeneca to Build $1.5 Billion Cancer Drug Manufacturing Facility in Singapore
May 20, 2024, 06:51 AM
AstraZeneca is planning to build a $1.5 billion manufacturing facility in Singapore to enhance its portfolio of antibody-drug conjugates (ADCs). This investment aims to bolster the production of a promising category of cancer-killing drugs. The Anglo-Swedish drugmaker announced the plan on Monday, highlighting its commitment to expanding its capabilities in the oncology sector. The move also signals a shift in the drug industry as companies increasingly split from China.
View original story
Oncology • 33%
Biopharmaceuticals • 33%
Rare Diseases • 33%
Oncology • 25%
Biopharmaceuticals • 25%
Rare diseases • 25%
Other • 25%
Less than 5 • 25%
5 to 9 • 25%
10 to 14 • 25%
15 or more • 25%
0-5 • 20%
6-10 • 20%
11-15 • 20%
16-20 • 20%
More than 20 • 20%
Oncology • 25%
Cardiovascular • 25%
Neurology • 25%
Immunology • 25%
$50 Billion • 25%
$60 Billion • 25%
$70 Billion • 25%
$80 Billion • 25%
Q3 2026 • 25%
Q1 2026 • 25%
Q2 2026 • 25%
Q4 2026 • 25%